Sign In
Buy CTMX
$3.22
+0.0600 (+1.90%)
At Close: Jun 03, 2026
CytomX Therapeutics to Present at Upcoming November Investor Conferences
08:00am, Thursday, 11'th Nov 2021
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCar
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2021 Results - Earnings Call Transcript
08:37am, Sunday, 07'th Nov 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2021 Results - Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
07:49pm, Thursday, 04'th Nov 2021
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.67% and -5.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stoc
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
08:00am, Thursday, 28'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
CytomX Therapeutics Announces New Employment Inducement Grants
08:00am, Monday, 18'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves
CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors
08:00am, Monday, 04'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
CytomX: Solving A Critical Problem In The High-Value ADC Space
08:00am, Wednesday, 15'th Sep 2021
CTMX is trading at cash. They have major collaborations.
CytomX Therapeutics Announces New Employment Inducement Grants
08:00am, Tuesday, 17'th Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2021 Results - Earnings Call Transcript
10:26am, Sunday, 08'th Aug 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2021 Results - Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates
07:01pm, Thursday, 05'th Aug 2021
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -15.38% and -10.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?
04:47pm, Thursday, 29'th Jul 2021
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
08:00am, Thursday, 29'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi
Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
11:36am, Wednesday, 14'th Jul 2021
CytomX Therapeutics (CTMX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript
04:31pm, Sunday, 09'th May 2021
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript
